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Summary. Successful strategies by which to effectively
recruit and retain academic subspecialists in benign
haematology have not been established. To evaluate
the effectiveness of a grant-funded, mentored fellow-
ship with respect to retention and early career goals in
haemostasis/thrombosis, we sought to compare out-
comes for graduates of a grant-funded, mentored
fellowship training programme in haemostasis/throm-
bosis [the National Hemophilia Foundation (NHF)-
Baxter Clinical Fellowship Award] during conventional
haematology/oncology fellowship training (cases), vs.
their training peers who were graduates of conven-
tional haematology/oncology fellowship training alone
(controls), via a nested case-control survey study.
Survey response rate was 85% (11/13) for cases and
90% (9/10) for controls. All respondents had pursued
careers in academic haematology/oncology. Median
(range) percent time spent in benign haematology
postfellowship was 98% (70–100%) for cases vs. 0%
(0–20%) for controls. Time spent in research was
significantly greater among cases than controls (median
80% [range: 42–90%] vs. 55% [10–80%], respec-
tively; P = 0.01). By years 3–4 postfellowship, median
annual number of peer-reviewed publications was
higher for cases than controls (3.5 vs. 1.0; P = 0.01).
Cases were also more successful in grant funding
(including K-awards). These data suggest that a grant-
funded, mentored fellowship training programme in
haemostasis/thrombosis may be superior to conven-
tional haematology/oncology fellowship training alone
with respect to outcomes of retention in clinical care/
research, early-career grant funding and publication
productivity.
Keywords: benign haematology, coagulation, fellowship,
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Introduction
Successful strategies by which to effectively recruit, train
and retain academic subspecialists in benign haematol-
ogy remain unclear. In the UK, a particular challenge
has been identified for transfusion medicine subspecial-
ists [1], and throughout Europe and the United States
for haemophilia treatment experts [2]. Innovative means
of recruitment into training programmes have been
deemed critical to the future of these areas and the
academic haematology subspeciality in particular.
The National Hemophilia Foundation (NHF)-Baxter
Clinical Fellowship Program, funded through an
educational grant by Baxter Biosciences, was developed
in 2002 to educate and train new physicians in
comprehensive care and research for individuals with
bleeding and clotting disorders. ‘Centers of excellence’
within the Centers for Disease Control and Prevention
and Maternal and Child Health Bureau-established
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Hemophilia Treatment Center network were selected as
training sites for the Program following institutional
application, based on the following criteria: (i) estab-
lished haemophilia/thrombophilia treatment centre with
both clinical and research faculty, (ii) affiliation with
major universities and teaching hospitals, (iii) strong
track record and future plan for haemostasis/thrombosis
trainee recruitment, (iv) adequate patient base and
volume in haemostasis/thrombosis, (v) institutional
track record and resources for training, (vi) depth of
research training opportunities, and (vii) development
of a curriculum for education in: haemostasis; throm-
bosis; treatment of haemophilia, von Willebrand disease
and other bleeding disorders; and treatment of throm-
bophilia and thrombotic diseases. Via a peer review
process involving representatives of the NHF’s Medical
and Scientific Advisory Council, seventeen institutions
were approved for the Program, based upon fulfilment
of the aforementioned qualifications.
Approved institutions were subsequently invited to
nominate trainee candidates. Candidates were selected
for the NHF-Baxter Clinical Fellowship Award based
upon the following criteria: (i) medical degree, (ii)
eligibility for subspeciality board certification upon
completion of the 2-year fellowship, (iii) United States
citizenship or permanent resident status, (iv) qualifica-
tions and previous experience, (v) long-term goals,
including desire to remain in the haemostasis/thrombo-
sis field, and (vi) letters of recommendation provided by
the haemophilia/thrombophilia treatment centre Medi-
cal Director and from other faculty within the institu-
tion. The mentorship plan was not prescribed in detail
by the Program, but was comprised of the following
elements: (i) direct clinical and research mentorship by
an expert in haemostasis/thrombosis who has a leader-
ship role in a haemophilia/thrombophilia treatment
centre, (ii) regular mentorship interactions in clinical
care, research and career development, and (iii) gener-
ation and NHF panel review of semi-annual progress
reports addressing progress in clinical training, research
and scientific presentations/publications.
The objectives of the present study were to compare
outcomes of this grant-funded, mentored fellowship
training program in haemostasis/thrombosis during
conventional haematology/oncology fellowship train-
ing, vs. conventional haematology/oncology fellowship
training alone, via a nested case–control survey study.
In particular, we sought to evaluate retention into a
benign haematology career, time spent in research,
publication trajectory and grant funding success.
Materials and methods
Subjects and design
We conducted a nested case–control survey study
involving NHF-Baxter program trainees (cases) and
their contemporaneous institutional colleagues in
haematology/oncology fellowship training (controls).
A standardized survey was developed via a consensus
process involving the authors, and then produced in
web-based format. Prior to administration of the
survey, cases were contacted with a request to provide
(with permission) names and contact information for all
controls for whom this information was available via
their fellowship program, for the purposes of survey
research. Trainees who had not yet completed fellow-
ship were excluded. All cases and controls were then
emailed a brief description of the study, along with a
request to complete the survey via a link provided in the
email, as well as to upload their current (i.e. up to date)
curriculum vitae. To optimize response rates, personal-
ized follow-up email reminders were sent to all subjects
by one of the authors (NAG). The study was approved
by the Tulane University Institutional Review Board,
with waiver of written informed consent.
Data collection
Quantitative components of the survey used in the
present analysis are shown in Fig. 1. Additional data
fields from the curriculum vitae included number of
publications and all grant funding amounts (measured
in direct costs, excluding NHF-Baxter Clinical Fellow-
ship Award funding); these data were reported for the
2-year period immediately preceding, the period during,
the 2-year period immediately after, and years 3–4 after
fellowship training. Further data collection from the
curriculum vitae consisted of gender, current age and
time (in years) postfellowship entry to gaining appoint-
ment as assistant professor and to obtaining a National
Institutes of Health K08 or K23 award.
Statistical analyses
Descriptive statistics were used to define distributions of
continuous variables and frequencies (i.e. proportions)
of categorical variables. Continuous data were com-
pared between case and control groups by Mann–
Whitney U-test, and proportions were compared
between groups via chi-squared test or Fisher’s exact
test, as appropriate based on cell frequencies in two-by-
two tables. All hypothesis tests were two-tailed, with a
P-value of less than 0.05 considered to be statistically
significant. Statistical analyses employed sas 9.1 soft-
ware (SAS Institute, Cary, NC, USA).
Results
Survey response rate was 85% (11/13) for cases and 90%
(9/10) for controls. Ninety per cent of respondents had
trained in paediatric programmes. Distribution of cases
and controls (respectively, by institution) was as follows:
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The Children’s Hospital, University of Colorado (n = 2,
n = 3); Children’s Hospital of Philadelphia, University of
Pennsylvania (n = 2, n = 2); Department of Pediatrics,
University of Michigan (n = 2, n = 2); Department of
Medicine, Tulane University (n = 1, n = 1); Michigan
Children’s Hospital, Wayne State University (n = 1,
n = 1); Department of Pediatrics, University of Iowa
(n = 1, n = 0); Children’s Medical Center, Emory Uni-
versity (n = 1, n = 0); and Cincinnati Children’s Hospi-
tal, University of Cincinnati (n = 1, n = 0).
Demographic data and outcomes (excluding publica-
tion and grant funding trajectories) are given in Table 1.
Median (range) age at survey response was 39 years
(33–46 years), and did not differ between case and
control groups. Fifty per cent of respondents were
women, with similar gender distribution between
groups. All respondents had pursued careers in aca-
demic haematology/oncology. Median (range) per cent
time spent in benign haematology postfellowship was
98% (70–100%) for cases vs. 0% (0–20%) for controls,
and time spent in research was significantly greater
among cases than controls (median 80% [range: 42–
90%] vs. 55% [10–80%], respectively; P = 0.01).
Figure 2 displays peer-reviewed publication rates
over time, comparing cases vs. controls. By years 3–4
postfellowship, median annual number of peer-
1. In what year did you begin your clinical fellowship?
2. In what year did you end your clinical fellowship?
3. What is your current title(s)?
4. Upon completing your fellowship, what type of position did you take?
Haematology research – basic
Haematology research – clinical
Oncology research – basic
Oncology research – clinical
Haematology – Teaching
Haematology – Administration
Oncology – Teaching
Oncology – Administration
Haematology  – Other (explain)
Oncology – Other (explain)
5. Since the completion of your fellowship, how much of your time has been allocated
to the following? Please indicate up to 100%.
Benign Haematology
Malignant Haematology
Solid Tumors
Other: Please explain
6. Since the completion of your fellowship, how has your time been allocated? Please
indicate up to 100%.
Clinical
Research- basic
Research- clinical
Teaching
Administration
Other (explain)
7. On a scale of 1 to 5, with 1 being the lowest, please rate your current level of knowledge
for each of the following areas:
Haemostasis
Thrombosis
Other benign haematology
Transfusion medicine
Coagulation laboratory technique/skills
Clinical research
Basic research methodologies
8. Please provide your current curriculum vitae, including all past and current grant funding.
Fig. 1. Survey questions used in the study
analysis.
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reviewed publications was higher for cases than controls
(3.5 vs. 1.0; P = 0.01). Figure 3 shows grant funding
trajectory for cases vs. controls, in annualized direct
costs, excluding NHF-Baxter Clinical Fellowship
Award funding. Although not statistically significant,
median annual grant dollars were appreciably higher
among cases than controls ($80 000 vs. $23 000;
P = 0.20), as was the percentage of individuals who
obtained K awards within 5 years of beginning fellow-
ship (33% vs. 0%; P = 0.21 [Table 1]).
Table 1. Demographic characteristics and outcomes (excluding publication and grant funding trajectories, shown in Figs 1 and 2) of former NHF-Baxter
trainees (cases) and contemporaneous institutional haematology/oncology fellowship trainees (controls).
Characteristics Cases (n = 11) Controls (n = 9) P-value
Demographics
Gender (female) 5 (45%) 5 (56%)
Median (range) age at fellowship entry 39 years (33–43 years) 39 years (33–46 years)
Outcomes postfellowship
Median (range) time from fellowship entry to assistant professor
(academic practice physicians only)
3.5 years (3–5 years) 7 years (6–8 years) <0.001
Time spent in benign haematology 98% (70–100%) 0% (0–20%) NA
Time spent in research 80% (42–90%) 55% (10–80%) 0.01
Attained NIH K23/K08 award within 5 years of fellowship entry 3/9 (33%) 0/8 (0%) NE
NA, not appropriate for comparison (e.g. concern for selection bias); NE, not evaluable.
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Fig. 3. Grant Funding Trajectory for NHF/
Baxter Fellowship Program Awardees (Group 1,
n = 11) vs. Institutional Hem/Onc Fellowship
Peers (Group 0, n = 9).
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Discussion
The findings of this nested case–control survey study
suggest that a grant-funded, mentored fellowship
training program in haemostasis/thrombosis may be
superior to conventional haematology/oncology fellow-
ship training with respect to retention of physicians in
benign haematology clinical care and research, and
academic outcome measures such as publication and
grant funding trajectories. The study has important
potential implications for future training in haemosta-
sis/thrombosis and perhaps other specialities in benign
haematology wherein recruitment and retention of
physician-investigators has been deemed a critical chal-
lenge. Key enhancements of conventional fellowship
training—specifically, grant-funding and mentorship in
a particular area of subspeciality focus—likely serve as
strong contributors to the comparative success of the
grant-funded, mentored fellowship training pro-
gramme. For this reason, the authors believe that future
efforts at recruitment and retention of haemostasis/
thrombosis physician-investigators should emphasize
the development of grant-funded, mentored fellowship
training programmes to augment conventional haema-
tology/oncology training.
A national decline in academic subspecialists and
trainees in benign haematology has been emphasized by
the American Society of Hematology [3]. This trend is
exacerbated by the economic disparity between aca-
demic and private practice physician salaries in haema-
tology/oncology, the latter of which emphasizes
competence in the management of malignant diseases.
A survey study of adult haematology/oncology fellow-
ship program directors revealed that only 24% of
graduating trainees pursued an academic career [4].
Furthermore, a survey study of adult and paediatric
haematology/oncology fellowship program directors
demonstrated that benign haematology serves as the
clinical focus for only 5–6% of adult training graduates
in private practice or academia, and for less than 1% of
paediatric graduates in private practice; by contrast,
13% of paediatric haematology/oncology training
programme graduates who remained in academia pur-
sued benign haematology as a clinical focus [5].
Various curricula for training and/or competence in
benign haematology have been reported in the past
several years. On behalf of the American Society of
Pediatric Hematology/Oncology (ASPHO), Hastings
and colleagues on the ASPHO Training Committee
outlined goals and core components for paediatric
haematology/oncology training. While both clinical
and research training were emphasized, mechanisms
for recruitment and retention in academic haematology/
oncology were outside the scope of the Committee’s
report [6]. Astermark and group, for the European
Association of Haemophilia and Allied Disorders,
described detailed competencies for clinical practice in
haemostasis/thrombosis, but strategies for recruitment
and retention into the field were not among the aims of
the consensus criteria [7]. Through a curriculum devel-
opment effort funded by the American Society of
Hematology, Abshire proposed criteria for clinical and
research training in benign haematology within a 2-year
adult Hematology fellowship program, which includes
3 months of inpatient benign haematology and
4–5 months of outpatient benign haematology in the
first year, and 75% time in benign haematology research
in the second year [8]. The research component empha-
sizesmentorship aswell as a faculty oversight committee.
The present findings for successful retention and early
career development in haemostasis/thrombosis build
upon prior literature in the field, with particular regard
to mentorship and training grant support in benign
haematology. In a survey study among US adult
hematology/oncology training programs, Gitlin and
co-workers investigated prognostic factors for success-
ful fellowship training towards a career as a physician-
investigator in haematology/oncology. This study
revealed that completion of a clinical research project,
presence of a clinical research track/programme, avail-
ability of a formal research curriculum, mentorship with
a faculty oversight committee and acquisition of inde-
pendent career development grant funding were all
independently associated with trainee pursuit of a
clinical research career in haematology/oncology [9].
Consistent with our observations in the present work,
a systematic review of 39 studies on the impact of
mentorship revealed positive associations with mentee
career choice, retention in academia and research
productivity, including publication and grant funding
[10]. ‘Extensive mentorship’ has also been emphasized
as a key ingredient in curriculum guidelines for training
in Haematology put forth by a subcommittee of the
American Society of Hematology Committee on Train-
ing Programs, to supplement the basic structure for
subspeciality training provided by the Accreditation
Council on Graduate Medical Education [11]. Yet,
adequate mentorship is not easy to achieve. As Kau-
shanski and Shattil noted in 2007 (and which remains
equally if not more relevant in 2011), ‘Now, more than
ever, we are in need of outstanding mentors, but… all
too often institutions do not reward mentoring’ [12]. By
targeting funds towards both trainees and their mentors,
perhaps future grant-funded, mentored fellowship train-
ing programmes haemostasis/thrombosis can overcome
a key institutional barrier to realizing the benefits of
mentored training in a subspeciality at risk of attrition.
A few limitations of the present work are noteworthy.
First, the possibility exists for selection bias, in that the
award of an NHF-Baxter traineeship may serve as an
a priori marker of academic success. However, this
potential bias was largely overcome by the selection of
controls who were contemporaneous peers matched by
institutional training programmes. Furthermore, this
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potential bias is also mitigated by the fact that no
significant difference in grant funding and publication
amounts were apparent between cases and controls in
the immediate prefellowship period. Secondly, the study
is challenged by a rather small sample size, rendering
statistical estimates imprecise. For this reason, the
findings are best described as preliminary, and warrant
further investigation. Third, while we observed that
time from beginning of fellowship training to acquisi-
tion of an Assistant Professor position was shorter
among cases than controls, this potential marker of
favourable outcome of the grant-funded, mentored
training programme could alternatively be explained
by greater funding availability and/or clinical demand
for junior faculty positions in haemostasis/thrombosis
than in other areas of haematology/oncology, upon
completion of fellowship training (i.e. in lieu of
Instructor positions). Fourth, our study and the Pro-
gram both assume that grant-funded, mentored training
in haemostasis/thrombosis during fellowship—as op-
posed to during a postfellowship Instructor period—is
the appropriate alternative/comparator to haemostasis/
thrombosis training during traditional haematology/
oncology fellowship. An alternative training strategy for
haemostasis/thrombosis is a postfellowship Instructor-
ship during which mentored training could take place in
this subspecialized area. However, given the challenges
of recruitment and retention in haemostasis/thrombosis
discussed previously, we favour the approach of earlier
immersion in grant-funded, mentored training. Lastly,
despite the success of the NHF-Baxter Program in
trainee recruitment and retention, adult (as opposed to
paediatric) trainees were few. Given the broader salary
gap between oncology and haematology in Internal
Medicine than Pediatrics, and the delay in focused
benign haematology training in some adult programmes
until the second year (at which time decisions regarding
research focus are being made), larger measures will be
necessary to boost recruitment and retention of trainees
into clinical and research careers in adult benign
haematology, including haemostasis/thrombosis. Not-
withstanding these potential limitations, the results of
this nested case–control survey study suggest that future
efforts at recruitment and retention of physician-inves-
tigators in haemostasis/thrombosis should emphasize
the development of grant-funded, mentored fellowship
training programmes to augment conventional haema-
tology/oncology training.
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